Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy.

摘要: The aim of this study was to evaluate the role platinum-containing chemotherapy for metastatic triple-negative breast cancer (TNBC) patients in terms response rate (RR) and progression-free survival. A second characterize clinical behavior at time relapse TNBC. We retrospectively analyzed outcomes with who received taxane-platinum as first- or second-line treatment, focusing on TN phenotype. In total, 257 Samsung Medical Center from 1999 2006. Of these patients, 106 available data estrogen (ER), progesterone (PgR) human epidermal growth factor receptor-2 (HER2) receptor status regimen treatment. overall RR TNBC 39%. This did not differ significantly those other phenotypes. death after (19 vs. 50 months, p = 0.037) survival (OS) (21 56 0.030) differed between non-TNBC. showed a unique locoregional infiltration pattern relapse, which might reflect its aggressive behavior. Despite similar chemotherapy, had shorter OS than implication phenotype poor prognostic is uncertain, because it needs be defined whether outcome related rapid growing characteristics tumor itself resistance drug therapy. Further prospective studies are warranted.